TANDEM DIABETES CARE INC
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $254.60M | $-0.31 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | $247.20M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 19, 2026 | During market hours | $290.40M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $249.30M | $-0.31 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | $240.70M | $-0.78 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 30, 2025 | During market hours | $234.40M | $-1.97 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | During market hours | $282.60M | $0.01 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | $244.00M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 21, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Gross margin | year ending December 31, 2026 | 56% to 57% | Maintained |
| Adjusted EBITDA marginnon-GAAP | year ending December 31, 2026 | 5% to 6% | Maintained |
| Non-cash charges included in cost of goods sold and operating expenses | year ending December 31, 2026 | $85.00M | Raised |
| non-cash, stock-based compensation expense | year ending December 31, 2026 | $65.00M | Lowered |
| depreciation and amortization expense | year ending December 31, 2026 | $20.00M | Lowered |
| Sales | year ending December 31, 2026 | $1.07B to $1.09B | Raised |
| U.S. sales | year ending December 31, 2026 | $730.00M to $745.00M | Lowered |
| International sales | year ending December 31, 2026 | $335.00M to $340.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Tandem Diabetes Care filed with the SEC
Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Fourth Quarter 2022 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Tandem Diabetes Care Appoints New Chair of Board of Directors
Results of operations · Executive or director change · EX-99.2 to Form 8-K
Tandem Diabetes Care Reports Preliminary, Unaudited 2022 Sales and Reaffirms 2023 Outlook
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2021 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces FDA Clearance for the t:slim X2 Insulin Pump to Bolus Using the t:connect Mobile App
Other events · EX-99.1 to Form 8-K
Tandem Diabetes Care Announces Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K